Lincoln Pharmaceuticals (NSE:LINCOLN, BOM:531633) has begun the trial run of a new manufacturing facility at Gandhinagar in Gujarat, India, according to a Wednesday filing to the Indian stock exchanges.
The new facility is expected to begin commercial production of active pharmaceutical ingredients in one to two years, subject to additional product permission received from the Food and Drugs Control Administration.
The facility has been set up with an investment of 40 million Indian rupees and will lead to a proposed capacity addition of 1.2 tons per annum.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。